140 related articles for article (PubMed ID: 9873732)
1. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin.
Dubowchik GM; Mosure K; Knipe JO; Firestone RA
Bioorg Med Chem Lett; 1998 Dec; 8(23):3347-52. PubMed ID: 9873732
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin.
Dubowchik GM; Firestone RA
Bioorg Med Chem Lett; 1998 Dec; 8(23):3341-6. PubMed ID: 9873731
[TBL] [Abstract][Full Text] [Related]
3. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity.
Dubowchik GM; Firestone RA; Padilla L; Willner D; Hofstead SJ; Mosure K; Knipe JO; Lasch SJ; Trail PA
Bioconjug Chem; 2002; 13(4):855-69. PubMed ID: 12121142
[TBL] [Abstract][Full Text] [Related]
4. Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs.
Abu Ajaj K; Biniossek ML; Kratz F
Bioconjug Chem; 2009 Feb; 20(2):390-6. PubMed ID: 19199576
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B.
Abu Ajaj K; Graeser R; Fichtner I; Kratz F
Cancer Chemother Pharmacol; 2009 Jul; 64(2):413-8. PubMed ID: 19229536
[TBL] [Abstract][Full Text] [Related]
6. Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-α) against murine fibrosarcoma.
Dai C; Fu Y; Li B; Wang Y; Zhang X; Wang J; Zhang Q
Sci China Life Sci; 2011 Feb; 54(2):128-38. PubMed ID: 21318482
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages.
Dubowchik GM; Radia S; Mastalerz H; Walker MA; Firestone RA; Dalton King H; Hofstead SJ; Willner D; Lasch SJ; Trail PA
Bioorg Med Chem Lett; 2002 Jun; 12(11):1529-32. PubMed ID: 12031335
[TBL] [Abstract][Full Text] [Related]
8. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
9. Development of dual-acting prodrugs for circumventing multidrug resistance.
Abu Ajaj K; Kratz F
Bioorg Med Chem Lett; 2009 Feb; 19(3):995-1000. PubMed ID: 19131246
[TBL] [Abstract][Full Text] [Related]
10. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological activity of protaxols.
Nicolaou KC; Riemer C; Kerr MA; Rideout D; Wrasidlo W
Nature; 1993 Jul; 364(6436):464-6. PubMed ID: 8101355
[TBL] [Abstract][Full Text] [Related]
12. Dipeptide derivatives of AZT: synthesis, chemical stability, activation in human plasma, hPEPT1 affinity, and antiviral activity.
Santos C; Morais J; Gouveia L; de Clercq E; Pannecouque C; Nielsen CU; Steffansen B; Moreira R; Gomes P
ChemMedChem; 2008 Jun; 3(6):970-8. PubMed ID: 18389514
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review).
Zhong YJ; Shao LH; Li Y
Int J Oncol; 2013 Feb; 42(2):373-83. PubMed ID: 23291656
[TBL] [Abstract][Full Text] [Related]
14. A new paclitaxel prodrug for use in ADEPT strategy.
Bouvier E; Thirot S; Schmidt F; Monneret C
Org Biomol Chem; 2003 Oct; 1(19):3343-52. PubMed ID: 14584798
[TBL] [Abstract][Full Text] [Related]
15. Application of enzymatically stable dipeptides for enhancement of intestinal permeability. Synthesis and in vitro evaluation of dipeptide-coupled compounds.
Friedrichsen GM; Jakobsen P; Taub M; Begtrup M
Bioorg Med Chem; 2001 Oct; 9(10):2625-32. PubMed ID: 11557350
[TBL] [Abstract][Full Text] [Related]
16. Polymeric prodrugs of mitomycin C designed for tumour tropism and sustained activation.
Seymour LW; Soyez H; De Marre A; Shoaibi MA; Schacht EH
Anticancer Drug Des; 1996 Jul; 11(5):351-65. PubMed ID: 8765529
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin B-Cleavable Cyclopeptidic Chemotherapeutic Prodrugs.
Herceg V; Bouilloux J; Janikowska K; Allémann E; Lange N
Molecules; 2020 Sep; 25(18):. PubMed ID: 32962018
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug.
Rodrigues ML; Carter P; Wirth C; Mullins S; Lee A; Blackburn BK
Chem Biol; 1995 Apr; 2(4):223-7. PubMed ID: 9383424
[TBL] [Abstract][Full Text] [Related]
19. Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release.
de Groot FM; Loos WJ; Koekkoek R; van Berkom LW; Busscher GF; Seelen AE; Albrecht C; de Bruijn P; Scheeren HW
J Org Chem; 2001 Dec; 66(26):8815-30. PubMed ID: 11749612
[TBL] [Abstract][Full Text] [Related]
20. Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs.
Toki BE; Cerveny CG; Wahl AF; Senter PD
J Org Chem; 2002 Mar; 67(6):1866-72. PubMed ID: 11895404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
